These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38450197)

  • 21. Direct comparison of magnetic resonance imaging and pathological shrinkage patterns of triple-negative breast cancer after neoadjuvant chemotherapy.
    Yoshikawa K; Ishida M; Kan N; Yanai H; Tsuta K; Sekimoto M; Sugie T
    World J Surg Oncol; 2020 Jul; 18(1):177. PubMed ID: 32693794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation methods for the efficacy of neoadjuvant chemotherapy for breast cancer.
    Wu JH; He JS; Ni Y; Wang XM
    Chin J Cancer; 2010 Feb; 29(2):223-8. PubMed ID: 20109356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The percentage of unnecessary mastectomy due to false size prediction using preoperative ultrasonography and MRI in breast cancer patients who underwent neoadjuvant chemotherapy: a prospective cohort study.
    Han Y; Jung JG; Kim JI; Lim C; Kim HK; Lee HB; Moon HG; Han W
    Int J Surg; 2023 Dec; 109(12):3993-3999. PubMed ID: 38258999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple-negative breast cancer: are the imaging findings different between responders and nonresponders to neoadjuvant chemotherapy?
    Kawashima H; Inokuchi M; Furukawa H; Kitamura S
    Acad Radiol; 2011 Aug; 18(8):963-9. PubMed ID: 21652233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
    Pang J; Wang S; Liao L; Liu X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial.
    Golshan M; Wong SM; Loibl S; Huober JB; O'Shaughnessy J; Rugo HS; Wolmark N; Ansell P; Maag D; Sullivan DM; Metzger-Filho O; Von Minckwitz G; Geyer CE; Sikov WM; Untch M
    Eur J Surg Oncol; 2020 Feb; 46(2):223-228. PubMed ID: 31606288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer.
    Park S; Yoon JH; Sohn J; Park HS; Moon HJ; Kim MJ; Kim EK; Kim SI; Park BW
    PLoS One; 2016; 11(2):e0149347. PubMed ID: 26866475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of the effects of chemotherapy on programmed death-ligand 1 expression in triple-negative breast cancer.
    Imanishi S; Morishima H; Gotoh T
    Jpn J Clin Oncol; 2022 Oct; 52(10):1167-1175. PubMed ID: 35766179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer.
    Jia Q; Xu J; Jiang W; Zheng M; Wei M; Chen J; Wang L; Huan Y
    Int J Med Sci; 2013; 10(2):110-8. PubMed ID: 23329881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.
    Bernemann C; Hülsewig C; Ruckert C; Schäfer S; Blümel L; Hempel G; Götte M; Greve B; Barth PJ; Kiesel L; Liedtke C
    Mol Cancer; 2014 Jul; 13():174. PubMed ID: 25033833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic performance of MRI for assessing axillary lymph node status after neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.
    Li Z; Ma Q; Gao Y; Qu M; Li J; Lei J
    Eur Radiol; 2024 Feb; 34(2):930-942. PubMed ID: 37615764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retraction: Ppm1b Negatively Regulates 3-Bromopyruvic Acid Induced Necroptosis in Breast Cancer Cells.
    Frontiers Editorial Office
    Front Oncol; 2021; 11():757083. PubMed ID: 34513719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast cancer subtypes affect the ultrasound performance for axillary lymph node status evaluation after neoadjuvant chemotherapy: a retrospective analysis.
    Fei J; Wang GQ; Meng YY; Zhong X; Ma JZ; Sun NN; Chen JJ
    Jpn J Clin Oncol; 2021 Oct; 51(10):1509-1514. PubMed ID: 34345909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
    Cortes J; Haiderali A; Huang M; Pan W; Schmid P; Akers KG; Park JE; Frederickson AM; Fasching PA; O'Shaughnessy J
    BMC Cancer; 2023 Aug; 23(1):792. PubMed ID: 37612624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retraction: Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1.
    Frontiers Editorial Office
    Front Oncol; 2021; 11():839904. PubMed ID: 35036357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retraction: MicroRNA-326 functions as a tumor suppressor in breast cancer by targeting ErbB/PI3K signaling pathway.
    Frontiers Editorial Office
    Front Oncol; 2023; 13():1298871. PubMed ID: 37881488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD10 expression as a potential predictor of pathological complete response in ER-negative and triple-negative breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.
    Dimitrov G; Shousha S; Troianova P
    Exp Mol Pathol; 2024 Feb; 135():104885. PubMed ID: 38281565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy.
    Jin Z; Wang W; Jiang N; Zhang L; Li Y; Xu X; Cai S; Wei L; Liu X; Chen G; Zhou Y; Liu C; Li Z; Jin F; Chen B
    PLoS One; 2015; 10(7):e0130286. PubMed ID: 26196284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.
    Li Y; Cui X; Yang YJ; Chen QQ; Zhong L; Zhang T; Cai RL; Miao JY; Yu SC; Zhang F
    Clin Breast Cancer; 2019 Oct; 19(5):326-332.e1. PubMed ID: 31176611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.